سوق علاج داء المبيضات - النمو ، والاتجاهات ، وتأثير COVID-19 ، والتنبؤات (2023 - 2028)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Deliverables

   2. 1.2 Study Assumptions

   3. 1.3 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Market Drivers

      1. 4.2.1 Increase in Number of Patients Affected by Candidiasis Infection

      2. 4.2.2 Growing Awareness for Candidiasis Infection

   3. 4.3 Market Restraints

      1. 4.3.1 Availability of Alternative Treatments

      2. 4.3.2 Narrow Pipeline Molecules

      3. 4.3.3 Competition from Herbal Medicines and Alternate Therapies

   4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 By Route of Administration

      1. 5.1.1 Injection

      2. 5.1.2 Ointment

      3. 5.1.3 Oral

   2. 5.2 By Drug Type

      1. 5.2.1 Polyene

      2. 5.2.2 Azole

      3. 5.2.3 Echinocandin

      4. 5.2.4 Other Types of Drugs

   3. 5.3 By Anatomy Type

      1. 5.3.1 Oral Candidiasis

      2. 5.3.2 Vulvovaginal Candidiasis

      3. 5.3.3 Cutaneous Candidiasis

      4. 5.3.4 Invasive Candidiasis

      5. 5.3.5 Systemic Candidiasis

   4. 5.4 By End-user

      1. 5.4.1 Hospitals

      2. 5.4.2 Clinics

      3. 5.4.3 Retail Pharmacies

      4. 5.4.4 Drug Stores

   5. 5.5 Geography

      1. 5.5.1 North America

         1. 5.5.1.1 United States

         2. 5.5.1.2 Canada

         3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

         1. 5.5.2.1 Germany

         2. 5.5.2.2 United Kingdom

         3. 5.5.2.3 France

         4. 5.5.2.4 Italy

         5. 5.5.2.5 Spain

         6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

         1. 5.5.3.1 China

         2. 5.5.3.2 Japan

         3. 5.5.3.3 India

         4. 5.5.3.4 Australia

         5. 5.5.3.5 South Korea

         6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle-East & Africa

         1. 5.5.4.1 GCC

         2. 5.5.4.2 South Africa

         3. 5.5.4.3 Rest of Middle-East & Africa

      5. 5.5.5 South America

         1. 5.5.5.1 Brazil

         2. 5.5.5.2 Argentina

         3. 5.5.5.3 Rest of South America

6. 6. COMPETITIVE LANDSCAPE

   1. 6.1 Company Profiles

      1. 6.1.1 Basilea Pharmaceuticals

      2. 6.1.2 Astellas

      3. 6.1.3 Ferrer Internacional

      4. 6.1.4 Pacgen Biopharmaceuticals

      5. 6.1.5 NovaDigm Therapeutics

      6. 6.1.6 Pevion Biotech

      7. 6.1.7 Amplyx Pharmaceuticals Inc.

      8. 6.1.8 Biomar Microbial Technologies

      9. 6.1.9 Cidara Therapeutics Inc.

      10. 6.1.10 Novabiotics Limited

   *List Not Exhaustive

7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS